Genomics technology has paved the way for a global and unbiased quantitative and qualitative assessment of the immune response. We have developed an Immune Array platform based on whole genome microarray analysis and a transcriptomic approach that is well suited to identify the mechanisms that lead to protective immunity induced by vaccines. We have previously used this platform to describe the very early induction (3 to 7 days) of a network of transcription factors that precede the development of highly integrated innate and adaptive immune responses induced by the Yellow Fever vaccine. In the Systems Biology Core E of this consortium, we aim to (i) provide a centralized sample, reporting, and data management and distribution framework, (ii) perform a comprehensive systems biology assessment of SIV vector-mediated innate and adaptive immune responses, (iii) provide rigorous biostatistical processing and power analysis of microarray and quantitative RT-PCR (QPCR) analysis, and (iv) provide projects and core-integrated immune correlate analysis for SIV vector immune characterization, selection, and study.
The aims of the core will be met via our commercial grade Laboratory Information Management System (LIMS), our SOP-driven, high-throughput. Immune Array platform for microarray analysis, our standardized, semiautomated bioinformatic reporting, and our template-driven data mapping of biological contexts/outcomes to integrate multiple projects and multiple OMIC platforms. We will use these leading edge technologies and bioinformatic strategies to assess the transcriptomic signatures that define early SIV-mediated host responses following different routes of mucosal challenge and the impact of SIV vector-mediated protection.
The impetus to provide an effective HIV vaccine has engaged multiple investigators across the globe and has largely been unsuccessful to date. This program project attempts to utilize novel vaccination strategies and novel technological approaches to develop vaccines in non-human primate models. The Systems Biology Core will use leading technologies in these proposed studies to develop novel vaccines that will eventually be tested in clinical trials in humans.
|Stephenson, Kathryn E; Neubauer, George H; Reimer, Ulf et al. (2015) Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods 416:105-23|
|Barouch, Dan H; Picker, Louis J (2014) Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12:765-71|
|Dugast, Anne-Sophie; Chan, Ying; Hoffner, Michelle et al. (2014) Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 9:e97229|
|Balandya, Emmanuel; Miller, Andrew D; Beck, Matthew et al. (2014) Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys. J Virol 88:3756-65|
|Barouch, Dan H; Michael, Nelson L (2014) Accelerating HIV-1 Vaccine Efficacy Trials. Cell 159:969-72|
|Li, Qingsheng; Zeng, Ming; Duan, Lijie et al. (2014) Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 193:3113-25|
|Whitney, James B; Hill, Alison L; Sanisetty, Srisowmya et al. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74-7|
|Teigler, Jeffrey E; Phogat, Sanjay; Franchini, Genoveffa et al. (2014) The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 88:1809-14|
|Shang, Liang; Smith, Anthony J; Duan, Lijie et al. (2014) NK cell responses to simian immunodeficiency virus vaginal exposure in naive and vaccinated rhesus macaques. J Immunol 193:277-84|
|Barouch, Dan H; Deeks, Steven G (2014) Immunologic strategies for HIV-1 remission and eradication. Science 345:169-74|
Showing the most recent 10 out of 20 publications